Glinka J, Clariá RS, Fratanoni E, Spina J, Mullen E, Ardiles V, Mazza O, Pekolj J, de Santibañes M, de Santibañes E. Malignant transformation of hepatocellular adenoma in a young female patient after ovulation induction fertility treatment: A case report. World J Gastrointestinal Surgery 2019; 11(4): 229-236 [PMID: 31123560 DOI: 10.4240/wjgs.v11.i4.229]
Corresponding Author of This Article
Juan Glinka, MD, Attending Doctor, Surgeon, HPB and Liver Transplantation Surgeon, Department of General Surgery, Hepato-bilio-pancreatic Unit, Hospital Italiano de Buenos Aires, Juan D. Perón 4190, Buenos Aires C1181ACH, Argentina. juan.glinka@hospitalitaliano.org.ar
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointestinal Surgery. Apr 27, 2019; 11(4): 229-236 Published online Apr 27, 2019. doi: 10.4240/wjgs.v11.i4.229
Malignant transformation of hepatocellular adenoma in a young female patient after ovulation induction fertility treatment: A case report
Juan Glinka, Rodrigo Sanchez Clariá, Eugenia Fratanoni, Juan Spina, Eduardo Mullen, Victoria Ardiles, Oscar Mazza, Juan Pekolj, Martín de Santibañes, Eduardo de Santibañes
Juan Glinka, Rodrigo Sanchez Clariá, Eugenia Fratanoni, Victoria Ardiles, Oscar Mazza, Juan Pekolj, Martín de Santibañes, Eduardo de Santibañes, Department of General Surgery, Hepato-bilio-pancreatic Unit, Hospital Italiano de Buenos Aires, Buenos Aires C1181ACH, Argentina
Juan Spina, Department of Radiology, Hospital Italiano de Buenos Aires, Buenos Aires C1181ACH, Argentina
Eduardo Mullen, Department of Surgical Pathology, Hospital Italiano de Buenos Aires, Buenos Aires C1181ACH, Argentina
Author contributions: Glinka J and Fratantoni E designed the report; Fratantoni E collected the patient’s clinical data; Spina J and Mullen E provided relevant figures; Glinka J, Clariá RS, Ardiles V, Pekolj J, Mazza O, de Santibañes M and de Santibañes E analysed the data and wrote the paper.
Informed consent statement: Consent was obtained from the patient for publication.
Conflict-of-interest statement: The authors declare that no conflict of interest exists.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Juan Glinka, MD, Attending Doctor, Surgeon, HPB and Liver Transplantation Surgeon, Department of General Surgery, Hepato-bilio-pancreatic Unit, Hospital Italiano de Buenos Aires, Juan D. Perón 4190, Buenos Aires C1181ACH, Argentina. juan.glinka@hospitalitaliano.org.ar
Telephone: +54-11-49814501
Received: February 25, 2019 Peer-review started: February 25, 2019 First decision: March 11, 2019 Revised: March 26, 2019 Accepted: April 23, 2019 Article in press: April 23, 2019 Published online: April 27, 2019 Processing time: 61 Days and 12.1 Hours
Abstract
BACKGROUND
Hepatocellular adenoma (HCA) is a rare benign liver tumor usually affecting young women with a history of prolonged use of hormonal contraception. Although the majority is asymptomatic, a low proportion may have significant complications such as bleeding or malignancy. Despite responding to the hormonal stimulus, the desire for pregnancy in patients with small HCA is not contraindicated. However, through this work we demonstrate that intensive hormonal therapies such as those used in the treatment of infertility can trigger serious complications
CASE SUMMARY
A 33-year-old female with a 10-year history of oral contraceptive use was diagnosed with a hepatic tumor as an incidental finding in an abdominal ultrasound. The patient showed no symptoms and physical examination was unremarkable. Laboratory functional tests were within normal limits and tests for serum tumor markers were negative. An abdominal magnetic resonance imaging (MRI) was performed, showing a 30 mm × 29 mm focal lesion in segment VI of the liver compatible with HCA or Focal Nodular Hyperplasia with atypical behavior. After a total of six years of follow-up, the patient underwent ovulation induction treatment for infertility. On a following MRI, a suspected malignancy was warned and hence, surgery was decided. The surgical specimen revealed malignant transformation of HCA towards trabecular hepatocarcinoma with dedifferentiated areas. There was non-evidence of tumor recurrence after three years of clinical and imaging follow-up.
CONCLUSION
HCAs can be malignant regardless its size and low-risk appearance on MRI when an ovultation induction therapy is indicated.
Core tip: As far as we know, this is the first report of a case involving a young woman with a small hepatocellular adenoma (HCA) with a stable behavior in a 6-year follow-up, who developed imaging changes suggesting malignancy after performing ovulation induction treatment. The patient underwent surgery due to diagnostic uncertainty, and the pathology report confirmed its malignancy. Therefore, we conclude that HCAs can be malignant regardless its size and low-risk appearance on magnetic resonance imaging when a hormone therapy is indicated.